BFS
NTLA icon

Bare Financial Services’s Intellia Therapeutics NTLA Stock Holding History

Bare Financial Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$677 Sell
40
-38
-49% -$532 ﹤0.01% 1538
2026
Q1 		$1K Buy
+78
New +$994 ﹤0.01% 1250

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Bare Financial Services's NTLA Position: Q2 2026 in Review

Bare Financial Services reduced its Intellia Therapeutics (NTLA) stake by 49% in Q2 2026, selling an estimated $532 and leaving 40 shares worth $677. The position accounts for ﹤0.01% of the portfolio, ranked #1538.

Bare Financial Services first reported a position in NTLA in Q1 2026 and has held it in 2 quarters since. The position peaked at $1K in Q1 2026. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Bare Financial Services held 40 shares of Intellia Therapeutics worth $677 as of Q2 2026.
  • Bare Financial Services sold 38 Intellia Therapeutics shares in Q2 2026, an estimated $532.
  • Intellia Therapeutics made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1538 holding.
  • Bare Financial Services first reported a position in Intellia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Bare Financial Services's Intellia Therapeutics position peaked at $1K in Q1 2026.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.